Stock data
Janux Therapeutics, Inc. (JANX)
Janux Therapeutics, Inc. (JANX) reported net income of -US$113.62M for fiscal 2025. The figures below come from the company's SEC filings.
Annual results
Data as of 2025-12-31
| Fiscal year | Revenue | Gross profit | Operating income | Net income | Diluted EPS |
|---|---|---|---|---|---|
| 2025 | — | — | -US$157.67M | -US$113.62M | — |
| 2024 | — | — | -US$98.85M | -US$68.99M | — |
| 2023 | — | — | -US$72.98M | -US$58.29M | — |
| 2022 | — | — | -US$67.09M | -US$63.06M | — |
| 2021 | — | — | -US$32.93M | -US$32.67M | — |
Quarterly results
Data as of 2026-06-30
| Quarter | Revenue | Net income | Diluted EPS |
|---|---|---|---|
| 2026-06-30 | — | -US$21.97M | — |
| 2026-03-31 | — | -US$24.36M | — |
| 2025-12-31 | — | -US$31.95M | — |
| 2025-09-30 | — | -US$24.31M | — |
| 2025-06-30 | — | -US$33.86M | — |
| 2025-03-31 | — | -US$23.51M | — |
| 2024-12-31 | — | -US$20.22M | — |
| 2024-09-30 | — | -US$28.06M | — |
Sources
- Source: SEC EDGAR company facts
Charts, drawing tools, and the P/E calculator are in the app, free to use.